二价与四价HPV疫苗免疫后7年疫苗型及非疫苗型中和抗体持久性
对12–15岁女孩随机接种三剂Cervarix®或Gardasil®后的头对头研究进行随访,发现针对疫苗型和非疫苗型的中和抗体在初始接种后7年仍可检测到。混合效应模型预测抗体滴度每5–7年下降约30%,长期Cervarix®抗体滴度预计比Gardasil®高3–4倍。
要点
- 接种后7年,疫苗型和非疫苗型中和抗体仍可检测到。
- 抗体滴度估计每5–7年下降30%。
- 长期Cervarix®抗体滴度预计比Gardasil®高3–4倍。
核心结论
- 疫苗型和非疫苗型中和抗体在初始接种后7年仍可检测到,且预计非疫苗型抗体可维持多年。
研究设计与样本
- 对12–15岁女孩随机接种三剂Cervarix®或Gardasil®的头对头研究进行随访,使用混合效应模型预测15年抗体滴度下降。
主要发现
- 疫苗型和非疫苗型中和抗体在初始接种后7年仍可检测到。
- 研究期间疫苗型和非疫苗型中和抗体滴度估计每5–7年下降30%。
- 长期Cervarix®抗体滴度预计比Gardasil®高3–4倍。
- 对非疫苗型有初始应答者的抗体下降速率与疫苗型相似,预计可检测多年。
临床怎么用
- 支持HPV疫苗对疫苗型及非疫苗型的长期免疫持久性,为公共卫生干预提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bivalent (Cervarix®) and quadrivalent (Gardasil®) Human Papillomavirus (HPV) vaccines demonstrate remarkable efficacy against the targeted genotypes, HPV16 and HPV18, but also a degree of cross-protection against non-vaccine incorporated genotypes, HPV31 and HPV45. These outcomes seem to be supported by observations that the HPV vaccines induce high titer neutralizing antibodies against vaccine types and lower responses against non-vaccine types. Few data are available on the robustness of the immune response against non-vaccine types. We examined the durability of vaccine and non-vaccine antibody responses in a follow up of a head-to-head study of 12-15 year old girls initially randomized to receive three doses of Cervarix® or Gardasil® vaccine. Neutralizing antibodies against both vaccine and non-vaccine types remained detectable up to 7 years following initial vaccination and a mixed effects model was used to predict the decline in antibody titers over a 15 year period. The decline in vaccine and non-vaccine type neutralizing antibody titers over the study period was estimated to be 30% every 5-7 years, with Cervarix® antibody titers expected to remain 3-4 fold higher than Gardasil® antibody titers over the long term. The antibody decline rates in those with an initial response to non-vaccine types were similar to that of vaccine types and are predicted to remain detectable for many years. Empirical data on the breadth, magnitude, specificity and durability of the immune response elicited by the HPV vaccines contribute to improving the evidence base supporting this important public health intervention. Original trial: ClinicalTrials.gov NCT00956553.
引用
- Godi A, Panwar K, Haque M, et al. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine. 2019. PMID: 30926298. doi:10.1016/j.vaccine.2019.03.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。